{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T02:00:14Z","timestamp":1780970414187,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01507-w","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T12:15:54Z","timestamp":1777119354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton\u2019s tyrosine kinase inhibitor therapy"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-8341","authenticated-orcid":false,"given":"Yucai","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa C.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6536-1291","authenticated-orcid":false,"given":"Steven R.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9143-3316","authenticated-orcid":false,"given":"Laveniya","family":"Kugathasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1381-5810","authenticated-orcid":false,"given":"Anita","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1699-5666","authenticated-orcid":false,"given":"Ashlee","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor R.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Bond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kami J.","family":"Maddocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4461-0970","authenticated-orcid":false,"given":"Alexey","family":"Danilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Argao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran A.","family":"Nizamuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0459-6609","authenticated-orcid":false,"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1346-3157","authenticated-orcid":false,"given":"Natalie S.","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazneen B.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios N.","family":"Pongas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-9013","authenticated-orcid":false,"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evguenia","family":"Ouchveridze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5245-2354","authenticated-orcid":false,"given":"Aung M.","family":"Tun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"Baidoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8582-1219","authenticated-orcid":false,"given":"Muhamad","family":"Alhaj Moustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoey I.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9060-8911","authenticated-orcid":false,"given":"Javier L.","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip R.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9487-8345","authenticated-orcid":false,"given":"Craig A.","family":"Portell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Reagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2588-1943","authenticated-orcid":false,"given":"Christine E.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6360-3234","authenticated-orcid":false,"given":"Reid W.","family":"Merryman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Velayati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. Brian","family":"Greenwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew G.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-168X","authenticated-orcid":false,"given":"Preetesh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabarish R.","family":"Ayyappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9865-4517","authenticated-orcid":false,"given":"Eric","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren G.","family":"Banaszak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka A.","family":"Pophali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Stack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus R.","family":"Messmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur S.","family":"Narkhede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitkumar","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7431-8455","authenticated-orcid":false,"given":"Tamara K.","family":"Moyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3848-6136","authenticated-orcid":false,"given":"Nilanjan","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3616-7393","authenticated-orcid":false,"given":"Rahul S.","family":"Bhansali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-5271","authenticated-orcid":false,"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manali K.","family":"Kamdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Anna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Stanisic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-4376","authenticated-orcid":false,"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1867-0526","authenticated-orcid":false,"given":"Matthew J.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-178X","authenticated-orcid":false,"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"1507_CR1","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/ajh.26523","volume":"97","author":"P Jain","year":"2022","unstructured":"Jain P, Wang ML. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022;97:638\u201356.","journal-title":"Am J Hematol"},{"key":"1507_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","volume":"121","author":"R Delarue","year":"2013","unstructured":"Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. Blood. 2013;121:48\u201353.","journal-title":"Blood"},{"key":"1507_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388:565\u201375.","journal-title":"Lancet"},{"key":"1507_CR4","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","volume":"112","author":"CH Geisler","year":"2008","unstructured":"Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112:2687\u201393.","journal-title":"Blood"},{"key":"1507_CR5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","volume":"158","author":"CH Geisler","year":"2012","unstructured":"Geisler CH, Kolstad A, Laurell A, Jerkeman M, Raty R, Andersen NS, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012;158:355\u201362.","journal-title":"Br J Haematol"},{"key":"1507_CR6","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bjh.14241","volume":"175","author":"CW Eskelund","year":"2016","unstructured":"Eskelund CW, Kolstad A, Jerkeman M, Raty R, Laurell A, Eloranta S, et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175:410\u20138.","journal-title":"Br J Haematol"},{"key":"1507_CR7","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105:2677\u201384.","journal-title":"Blood"},{"key":"1507_CR8","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","volume":"377","author":"S Le Gouill","year":"2017","unstructured":"Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377:1250\u201360.","journal-title":"N Engl J Med"},{"key":"1507_CR9","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203\u201310.","journal-title":"Lancet"},{"key":"1507_CR10","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123:2944\u201352.","journal-title":"Blood"},{"key":"1507_CR11","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/JCO.18.00605","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, et al. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019;37:984\u201391.","journal-title":"J Clin Oncol"},{"key":"1507_CR12","doi-asserted-by":"publisher","first-page":"7503","DOI":"10.1200\/JCO.2016.34.15_suppl.7503","volume":"34","author":"MJ Rummel","year":"2016","unstructured":"Rummel MJ, Knauf W, Goerner M, Soeling U, Lange E, Hertenstein B, et al. Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). J Clin Oncol. 2016;34:7503.","journal-title":"J Clin Oncol"},{"key":"1507_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/hon.75_2631","volume":"37","author":"BT Hill","year":"2019","unstructured":"Hill BT, Switchenko JM, Martin P, Churnetski MC, Sawalha Y, Goyal S, et al. Maintenance rituximab is associated with improved overall survival in mantle cell lymphoma patients responding to induction therapy with bendamustine + rituximab (BR). Hematol Oncol. 2019;37:405\u20137.","journal-title":"Hematol Oncol"},{"key":"1507_CR14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1200\/JCO.21.02698","volume":"41","author":"P Martin","year":"2023","unstructured":"Martin P, Cohen JB, Wang M, Kumar A, Hill B, Villa D, et al. Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts. J Clin Oncol. 2023;41:541\u201354.","journal-title":"J Clin Oncol"},{"key":"1507_CR15","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.3324\/haematol.2022.282252","volume":"108","author":"M Di","year":"2023","unstructured":"Di M, Long JB, Kothari SK, Sethi T, Zeidan AM, Podoltsev NA, et al. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis. Haematologica. 2023;108:2218\u201323.","journal-title":"Haematologica"},{"key":"1507_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507\u201316.","journal-title":"N Engl J Med"},{"key":"1507_CR17","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","volume":"126","author":"ML Wang","year":"2015","unstructured":"Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126:739\u201345.","journal-title":"Blood"},{"key":"1507_CR18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391:659\u201367.","journal-title":"Lancet"},{"key":"1507_CR19","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1038\/s41375-019-0575-9","volume":"33","author":"M Wang","year":"2019","unstructured":"Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia. 2019;33:2762\u20136.","journal-title":"Leukemia"},{"key":"1507_CR20","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","volume":"26","author":"Y Song","year":"2020","unstructured":"Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, et al. Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton\u2019s tyrosine kinase. Clin Cancer Res. 2020;26:4216\u201324.","journal-title":"Clin Cancer Res"},{"key":"1507_CR21","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood.2021014162","volume":"139","author":"Y Song","year":"2022","unstructured":"Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, et al. Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022;139:3148\u201358.","journal-title":"Blood"},{"key":"1507_CR22","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","volume":"386","author":"ML Wang","year":"2022","unstructured":"Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med. 2022;386:2482\u201394.","journal-title":"N Engl J Med"},{"key":"1507_CR23","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1200\/JCO-25-00690","volume":"43","author":"M Wang","year":"2025","unstructured":"Wang M, Salek D, Belada D, Song Y, Jurczak W, Kahl BS, et al. Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma. J Clin Oncol. 2025;43:2276\u201384.","journal-title":"J Clin Oncol"},{"key":"1507_CR24","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1182\/blood-2025-885","volume":"146","author":"M Wang","year":"2025","unstructured":"Wang M, Paludo J, de Holanda Farias JS, Villa D, Forsyth C, John E, et al. Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: updated analysis of the phase 3 ECHO trial after 50 months of follow-up. Blood. 2025;146:885.","journal-title":"Blood"},{"key":"1507_CR25","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1182\/blood.2024025563","volume":"145","author":"A Kumar","year":"2025","unstructured":"Kumar A, Soumerai J, Abramson JS, Barnes JA, Caron P, Chhabra S, et al. Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation. Blood. 2025;145:497\u2013507.","journal-title":"Blood"},{"key":"1507_CR26","doi-asserted-by":"publisher","first-page":"e19525","DOI":"10.1200\/JCO.2023.41.16_suppl.e19525","volume":"41","author":"BD Shah","year":"2023","unstructured":"Shah BD, Xue M, Yang K, Liu S, Tang B. Real-world treatment patterns of Bruton tyrosine kinase inhibitors (BTKi) in patients with mantle cell lymphoma (MCL) in community oncology practices in the United States (US). J Clin Oncol. 2023;41:e19525\u2013e.","journal-title":"J Clin Oncol"},{"key":"1507_CR27","doi-asserted-by":"publisher","first-page":"3732","DOI":"10.1182\/blood-2024-208063","volume":"144","author":"T Phillips","year":"2024","unstructured":"Phillips T, Di M, Miller T, Wang J, Pierre A, Maglinte GA, et al. Evaluating reasons for differences in real-world (RW) clinical outcomes among patients with relapsed\/refractory mantle cell lymphoma (R\/R MCL) on covalent BTK inhibitors (cBTKis). Blood. 2024;144:3732.","journal-title":"Blood"},{"key":"1507_CR28","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/S0140-6736(25)01432-1","volume":"406","author":"DJ Lewis","year":"2025","unstructured":"Lewis DJ, Jerkeman M, Sorrell L, Wright D, Glimelius I, Poulsen CB, et al. Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2\/3 superiority trial. Lancet. 2025;406:1953\u201368.","journal-title":"Lancet"},{"key":"1507_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2217\/fon-2020-0794","volume":"17","author":"M Dreyling","year":"2021","unstructured":"Dreyling M, Tam CS, Wang M, Smith SD, Ladetto M, Huang H, et al. A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma. Future Oncol. 2021;17:255\u201362.","journal-title":"Future Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01507-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01507-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01507-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T01:23:26Z","timestamp":1780968206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01507-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1507"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01507-w","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"YW: Research funding (to institution): Incyte, InnoCare, Loxo Oncology, Eli Lilly, MorphoSys, Novartis, Genentech, Genmab, AbbVie, BeiGene, Merck; Advisory board (compensation to institution): Eli Lilly, Loxo Oncology, TG Therapeutics, Incyte, InnoCare, Kite Pharma, Janssen, BeiGene, AstraZeneca, Genmab, AbbVie; Consultancy (compensation to institution): InnoCare, AbbVie; Honoraria (to institution): Kite Pharma. DV: Honoraria and advisory board: Roche, Janssen, BeOne Medicines, AstraZeneca, AbbVie, Merck, Bristol Myers Squibb, Kite Pharma\/Gilead Sciences, Incyte, Kyowa Kirin, Eli Lilly, ONO Pharmaceutical. AK: Research support: AbbVie, Adaptive Biotechnologies, Celgene, Pharmacyclics, Loxo Oncology\/Eli Lilly, Seagen, Genentech, Incyte; Honoraria: AstraZeneca, Kite Pharma, Janssen, Genentech, Loxo Oncology\/Eli Lilly; Consulting: Genentech. DAB: Research funding: Incyte, Accutar Biotech, Nurix Therapeutics, Novartis, Kite Pharma\/Gilead Sciences, Bristol Myers Squibb, Genmab, BeOne Medicines; Consulting: Nurix Therapeutics, Kite Pharma\/Gilead Sciences, ADC Therapeutics, Novartis. KJM: Consulting\/Honoraria: AstraZeneca, AbbVie, Acerta Pharma, ADC Therapeutics, Autolus Therapeutics, BeOne Medicines, Bristol Myers Squibb, Caribou Biosciences, Genmab, Genentech, Janssen, Incyte, MorphoSys, Kite Pharma\/Gilead Sciences, Eli Lilly. AD: Consulting fees: AbbVie, AstraZeneca, BeOne Medicines, Genmab, Incyte, Janssen, Eli Lilly, Merck, Nurix Therapeutics, Regeneron; Research funding: BeOne Medicines, Genmab, Incyte, Eli Lilly, Merck, Nurix Therapeutics, Prelude Therapeutics, Regeneron. JR: Research support: AstraZeneca, Bristol Myers Squibb\/Celgene, Genentech, Daiichi Sankyo; Honoraria for consulting: AstraZeneca, Bristol Myers Squibb\/Celgene, Pfizer, Ipsen. BSK: Consulting: AbbVie, AstraZeneca, Bristol Myers Squibb, BeOne Medicines, Genentech, Roche, Incyte, Eli Lilly; Research support: BeOne Medicines, Roche, AstraZeneca. NSG: Research funding (to institution): Bristol Myers Squibb, Poseida Therapeutics, Cabaletta Bio, Merck, Regeneron; Honoraria: Bristol Myers Squibb, Novartis, Regeneron, Genentech, Incyte, ADC Therapeutics. GNP: Equity: Mevox Ltd.; Consulting fees\/Honoraria: ADC Therapeutics, BeOne Medicines. ISL: Research support: Genentech, ADC Therapeutics, Genmab. AMT: Advisory board: ADC Therapeutics. MAM: Advisory board: Genentech; Research funding: AbbVie\/Genmab. JLM: Consulting: Pharmacyclics\/AbbVie, Bayer, Gilead Sciences\/Kite Pharma, BeiGene, Pfizer, Janssen, Celgene\/Bristol Myers Squibb, Kyowa Kirin, Alexion, Fosun Kite, Seagen, Karyopharm Therapeutics, Aurobindo Pharma, Verastem, Genmab, Sanofi Genzyme, Genentech\/Roche, ADC Therapeutics, Epizyme, Novartis, MorphoSys\/Incyte, MEI Pharma, TG Therapeutics, AstraZeneca, Eli Lilly; Research funding: Bayer, Gilead Sciences\/Kite Pharma, Celgene, Merck, Portola Pharmaceuticals, Incyte, Genentech, Pharmacyclics, Seagen, Janssen, Millennium Pharmaceuticals, Novartis, BeiGene, Bristol Myers Squibb; Honoraria: Targeted Oncology, OncLive, Curio Science, Aptitude Health, Physicians\u2019 Education Resource. CAP: Consulting: AbbVie, AstraZeneca, BeiGene, Genentech, Pfizer; Research funding: BeOne Medicines, Merck, Genentech, Loxo Oncology\/Eli Lilly, AstraZeneca\/Acerta Pharma, Seagen\/Pfizer. PMR: Research funding (to institution): Genentech, Pfizer. CER: Consulting fees: AstraZeneca, BeOne Medicines, Genentech, Incyte; Research funding (to institution): BeOne Medicines, Eli Lilly, Genentech. RWM: Advisory board: Genmab, Bristol Myers Squibb, AbbVie, Ipsen, Kite Pharma; Consulting: DG Medicines; Honoraria: Genmab, AbbVie; Research funding (to institution): Merck, Bristol Myers Squibb, Genmab, Genentech\/Roche. EM: Consultancy: AbbVie. NG: Research funding (to institution): Genentech\/Roche, AstraZeneca, Incyte\/MorphoSys, AbbVie; Consulting\/Honoraria: AbbVie, AstraZeneca, Pharmacyclics, Janssen, Bristol Myers Squibb, Gilead Sciences, BeiGene, Incyte, Roche\/Genentech, Genmab, Merck, Galapagos, Pfizer. RK: Research funding (to institution): Bristol Myers Squibb, Kite Pharma\/Gilead Sciences, Takeda, Genentech, Genmab, AbbVie, BeiGene, Merck; Advisory board: Kite Pharma\/Gilead Sciences, BeiGene, Genmab, AbbVie, Bristol Myers Squibb, Genentech\/Roche, AvenCell. JRC: No funding related to this research; unrelated research funding: Bristol Myers Squibb, Genentech, Genmab (to institution); personal compensation for data and safety monitoring committee service: Protagonist Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}